Search results for "Azone"

showing 10 items of 170 documents

Effects of PPARγ agonists on the expression of leptin and vascular endothelial growth factor in breast cancer cells.

2013

The obesity hormone leptin has been implicated in breast cancer development. Breast cancer cells express the leptin receptor and are able to synthesize leptin in response to obesity-related stimuli. Furthermore, leptin is a positive regulator of vascular endothelial growth factor (VEGF) and high levels of both proteins are associated with worse prognosis in breast cancer patients. Peroxisome proliferator-activated receptor γ (PPARγ) ligands are therapeutic agents used in patient with Type 2 diabetes and obesity which have recently been studied for their potential anti-tumor effect. Here, we studied if these compounds, ciglitazone and GW1929, can affect the expression of leptin and VEGF in b…

LeptinVascular Endothelial Growth Factor APhysiologySettore MED/06 - Oncologia MedicaClinical BiochemistryLigandschemistry.chemical_compoundCell MovementPromoter Regions Geneticskin and connective tissue diseasesReceptorGENE-EXPRESSIONLeptindigestive oral and skin physiologyVEGFGene Expression Regulation NeoplasticVascular endothelial growth factorROSIGLITAZONEACTIVATED-RECEPTOR-GAMMAMCF-7 CellsPIOGLITAZONEFemalemedicine.medical_specialtyCell SurvivalSp1 Transcription FactorBLADDER-CANCERBreast NeoplasmsBiologyBenzophenonesBreast cancerCiglitazoneInternal medicinemedicineHumansRNA MessengerViability assayBinding SitesLeptin receptorDose-Response Relationship DrugCell BiologyIN-VITROmedicine.diseaseTRANSACTIVATIONDIABETIC-PATIENTSPPAR gammaEndocrinologychemistryTyrosineTHIAZOLIDINEDIONESACTIVATED-RECEPTOR-GAMMA; BLADDER-CANCER; IN-VITRO; DIABETIC-PATIENTS; GENE-EXPRESSION; VEGF; PIOGLITAZONE; THIAZOLIDINEDIONES; TRANSACTIVATION; ROSIGLITAZONEHormone
researchProduct

Staphylococcal alpha-toxin provokes neutrophil-dependent cardiac dysfunction: role of ICAM-1 and cys-leukotrienes.

2002

The role of polymorphonuclear neutrophils (PMN) in septic myocardial dysfunction is presently unknown. Staphylococcus aureus infections are frequently associated with septic sequelae. Therefore, we perfused isolated rat hearts with low doses of α-toxin, the major staphylococcal exotoxin, followed by application of human PMN, N-formyl-methionyl-leucyl-phenylalanine, and arachidonic acid. In contrast to sham-perfused hearts (no α-toxin), a rise in coronary perfusion pressure (CPP) and a reduction of contractile function were noted, and cardiac expression of intercellular adhesion molecule (ICAM)-1 was detected by immunohistochemical methods and real-time PCR. Histological analysis and myelope…

LeukotrienesHeart diseasePhysiologyNeutrophilsNeutrophileBacterial ToxinsExotoxinsThiophenesIn Vitro Techniquesmedicine.disease_causePathogenesisHemolysin ProteinsPhysiology (medical)medicineAnimalsHumansICAM-1Arachidonic AcidToxinbusiness.industryMyocardiumHydrazonesHeartmedicine.diseaseIntercellular Adhesion Molecule-1RatsN-Formylmethionine Leucyl-PhenylalaninePerfusionStaphylococcus aureusImmunologyCirculatory systemCardiology and Cardiovascular MedicinebusinessOligonucleotide ProbesExotoxinAmerican journal of physiology. Heart and circulatory physiology
researchProduct

Potential biological role of laccase from the sponge Suberites domuncula as an antibacterial defense component

2014

Abstract Background Laccases are copper-containing enzymes that catalyze the oxidation of a wide variety of phenolic substrates. Methods We describe the first poriferan laccase from the marine demosponge Suberites domuncula. Results This enzyme comprises three characteristic multicopper oxidase homologous domains. Immunohistological studies revealed that the highest expression of the laccase is in the surface zone of the animals. The expression level of the laccase gene is strongly upregulated after exposure of the animals to the bacterial endotoxin lipopolysaccharide. To allow the binding of the recombinant enzyme to ferromagnetic nanoparticles, a recombinant laccase was prepared which con…

LipopolysaccharidesMolecular Sequence DataBiophysicsMulticopper oxidaseFerric CompoundsLigninBiochemistryMichaelis–Menten kineticsGene Expression Regulation EnzymologicSubstrate Specificitychemistry.chemical_compoundEscherichia coliAnimalsLigninAmino Acid SequenceMolecular BiologyPhylogenyLaccasechemistry.chemical_classificationDose-Response Relationship DrugSequence Homology Amino AcidbiologyReverse Transcriptase Polymerase Chain ReactionChemistryLaccaseHydrazonesSubstrate (chemistry)biology.organism_classificationRecombinant ProteinsAnti-Bacterial AgentsUp-RegulationSuberites domunculaKineticsEnzymeBiochemistryBiocatalysisNanoparticlesSuberitesOxidation-ReductionIron oxide nanoparticlesBiochimica et Biophysica Acta (BBA) - General Subjects
researchProduct

Phenoloxidases in ascidian hemocytes: characterization of the pro-phenoloxidase activating system.

2003

The phenoloxidase (PO) activity of the hemocytes lysate supernatant from three ascidians species, assayed by means of 3-methyl-2-benzothiazolinone hydrazone hydrochloride, have been compared. PO-containing hemocytes were identified by a cytochemical reaction and the enzymatic activity measured by a spectrophotometric assay of lysate supernatant from hemocyte populations separated on a discontinuous Percoll density gradient. In Styela plicata, the enzyme appeared to be contained in morula cells only. In Ciona intestinalis, PO activity was shown in univacuolar refractile granulocyte and granular hemocyte. In Phallusia mammillata both compartment cell and granular hemocytes were positive. Enzy…

LysisHemocytesCiona intestinaliCell separationPhysiologySettore BIO/05 - ZoologiaHemocyteBiologyTunicateBiochemistryEnzyme activatormedicineAnimalsCiona intestinalisPhallusia mammillataBenzothiazolesUrochordataMolecular BiologyPolyacrylamide gel electrophoresischemistry.chemical_classificationMonophenol MonooxygenaseImmunityHydrazonesTrypsinbiology.organism_classificationMolecular biologyEnzyme ActivationThiazolesEnzymeStyela plicatachemistryStyela plicataPhenoloxidasePercollmedicine.drugComparative biochemistry and physiology. Part B, Biochemistrymolecular biology
researchProduct

Synthesis and pharmacological evaluation of 1-methyl-5- [substituted-4(3H)-oxo-1,2,3-benzotriazin-3-yl]-1H-pyrazole-4-acetic acid derivatives

1998

Several new 1-methyl-5-[substituted-4-oxo-1,2,3-benzotriazin-3-yl] -1H-pyrazole-4-acetic acids and their ethyl ester derivatives were prepared. The compounds were tested for analgesic and antiinflammatory activities, acute toxicity, ulcerogenic effect, and as in vitro inhibitors of 3 alpha-hydroxysteroid dehydrogenase (3 alpha-HSD), since it is claimed that the inhibition of such an enzyme predicts in vivo antiinflammatory activity. Some compounds were more active than phenylbutazone in the phenylbenzoquinone and acetic acid peritonitis tests, and equiactive to the same drug in the carrageenin paw edema test. All the compounds inhibited the 3 alpha-HSD, but no correlation was observed with …

Male3-Hydroxysteroid DehydrogenasesStereochemistryAnti-Inflammatory AgentsPharmaceutical SciencePyrazoleChemical synthesisMicechemistry.chemical_compoundAcetic acidIn vivoDrug DiscoveryPhenylbutazonemedicineAnimalsEnzyme InhibitorsAnalgesicsbiology3-alpha-Hydroxysteroid Dehydrogenase (B-Specific)Acute toxicityRatschemistryEnzyme inhibitorToxicitybiology.proteinPyrazolesmedicine.drugIl Farmaco
researchProduct

Fluorescent benzofurazan-cholic acid conjugates for in vitro assessment of bile acid uptake and its modulation by drugs.

2009

One of the most common mechanisms of hepatotoxicity is drug-induced cholestasis. Hence, new approaches for screening the cholestatic potential of drug candidates are desirable. In this context, we describe herein the use of synthetic 4-nitrobenzo-2-oxa-1,3-diazole (NBD) fluorescent conjugates of cholic acid (ChA) at positions 3alpha, 3beta, 7alpha, and 7beta for in vitro assessment of bile acid uptake. All the conjugates show a strong absorption band between 400 and 550 nm and have a fluorescence quantum yield of approximately 0.45, with an emission maximum centered at approximately 530 nm. After their photophysical characterization, 3alpha-, 3beta-, 7alpha-, and 7beta-NBD-ChA were used to …

MaleCell Membrane Permeabilitymedicine.drug_classPhotochemistrySodiumchemistry.chemical_elementCholic AcidBiochemistryBile Acids and SaltsRats Sprague-Dawleychemistry.chemical_compoundTroglitazoneCholestasisIn vivoCyclosporin aDrug DiscoverySodium citratemedicineAnimalsGeneral Pharmacology Toxicology and PharmaceuticsChromansFluorescent DyesPharmacologyBenzoxazolesBile acidOrganic ChemistryCholic acidmedicine.diseaseFlow CytometryFluorescenceRatschemistryBiochemistryHepatocytesMolecular MedicineThiazolidinedionesChemMedChem
researchProduct

Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately …

2017

Background The best treatment option for patients with type 2 diabetes in whom treatment with metformin alone fails to achieve adequate glycaemic control is debated. We aimed to compare the long-term effects of pioglitazone versus sulfonylureas, given in addition to metformin, on cardiovascular events in patients with type 2 diabetes. Methods TOSCA.IT was a multicentre, randomised, pragmatic clinical trial, in which patients aged 50–75 years with type 2 diabetes inadequately controlled with metformin monotherapy (2–3 g per day) were recruited from 57 diabetes clinics in Italy. Patients were randomly assigned (1:1), by permuted blocks randomisation (block size 10), stratified by site and…

MaleDiabetes and Metabolism ipoglycemic drugs cardiovascualr eventSettore MED/09 - Medicina Internaendocrine system diseasesIMPACTpioglitazone versus sulfonylureasEndocrinology Diabetes and MetabolismGLIMEPIRIDEDiabetes cardiovascular events metformin pioglitazone sulphonylureasType 2 diabetes030204 cardiovascular system & hematologyInternal Medicine; Endocrinology Diabetes and Metabolism; Endocrinologylaw.inventionSettore MED/13 - EndocrinologiaGlibenclamide0302 clinical medicineRandomized controlled triallawGLYCEMIC CONTROLGliclazideInternal medicinediabetes and metabolismRISKeducation.field_of_studydiabetesIncidenceInternal medicine; endocrinology diabetes and metabolism; endocrinologyMiddle AgedINSULINMetforminMetforminTreatment OutcomeEditorialsulphonylureasCardiovascular DiseasesCombinationDrug Therapy CombinationFemaleType 2medicine.drugmedicine.medical_specialtyPopulation030209 endocrinology & metabolismAged; Cardiovascular Diseases; Diabetes Mellitus Type 2; Drug Therapy Combination; Female; Humans; Hypoglycemic Agents; Incidence; Male; Metformin; Middle Aged; Pioglitazone; Sulfonylurea Compounds; Thiazolidinediones; Treatment OutcomeCardiovascular events03 medical and health sciencesendocrinologyGLUCOSE-LOWERING DRUGSDrug TherapyInternal medicineDiabetes MellitusmedicineHumansHypoglycemic AgentssulfonylureaseducationTOSCA.ITAgedPioglitazonebusiness.industryMORTALITYnutritional and metabolic diseasesInsulin resistancemedicine.diseaseSurgeryGlimepirideSulfonylurea CompoundsDiabetes Mellitus Type 2Diabetes Mellitus; Pioglitazone; Insulin resistanceThiazolidinedionesbusinessFOLLOW-UPPioglitazone
researchProduct

Investigation of the vascular and pleiotropic effects of atorvastatin and pioglitazone in a population at high cardiovascular risk.

2008

We investigated the effect of atorvastatin monotherapy and combined treatment with atorvastatin and pioglitazone on intima-media thickness, vascular function and the cardiovascular risk profile. In all, 148 patients (76 male, 72 female; aged 61.4±6.5 years; body mass index [BMI] 29.2±4.1 kg/m2; mean±SD) with increased cardiovascular (CV) risk factors were randomised. Intima-media thickness (IMT), the augmentation index (Aix@75), the microvascular response to acetylcholine (LDF), lipid status, and plasma levels of intact proinsulin, adiponectin, interleukin-6 (IL-6), monocyte chemotactic protein-1 (MCP-1), matrix metalloproteinase-9 (MMP-9), sCD40L, P-selectin, tissue plasminogen activator …

MaleEndocrinology Diabetes and MetabolismAtorvastatinBlood lipidsBlood Pressurechemistry.chemical_compoundGermanyAtorvastatinMedicineProspective StudiesSkinUltrasonographyeducation.field_of_studymedicine.diagnostic_testMiddle AgedLipidsTreatment OutcomeCardiovascular DiseasesRadial ArteryDrug Therapy CombinationFemaleInflammation MediatorsCardiology and Cardiovascular Medicinemedicine.drugmedicine.medical_specialtyCarotid Artery CommonPopulationRisk AssessmentDouble-Blind MethodInternal medicineInternal MedicineHumansPyrroleseducationAgedAdiponectinPioglitazonebusiness.industryCholesterolMicrocirculationAtherosclerosisEndocrinologychemistryHeptanoic AcidsThiazolidinedionesHydroxymethylglutaryl-CoA Reductase InhibitorsbusinessLipid profilePioglitazoneLipoproteinDiabetesvascular disease research
researchProduct

Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-l…

2009

Udgivelsesdato: 2009-Jun-20 BACKGROUND: Rosiglitazone is an insulin sensitiser used in combination with metformin, a sulfonylurea, or both, for lowering blood glucose in people with type 2 diabetes. We assessed cardiovascular outcomes after addition of rosiglitazone to either metformin or sulfonylurea compared with the combination of the two over 5-7 years of follow-up. We also assessed comparative safety. METHODS: In a multicentre, open-label trial, 4447 patients with type 2 diabetes on metformin or sulfonylurea monotherapy with mean haemoglobin A(1c) (HbA(1c)) of 7.9% were randomly assigned to addition of rosiglitazone (n=2220) or to a combination of metformin and sulfonylurea (active con…

MaleMyocardial InfarctionAdministration OralType 2 diabeteslaw.inventionFractures BoneRandomized controlled triallawNeoplasmsClinical endpointMyocardial infarctionrosiglitazone; cardiovascular outcomesProspective StudiesDiureticsGeneral MedicineMiddle AgedMetforminMetforminHospitalizationStrokeDrug Therapy CombinationFemaleRosiglitazonemedicine.drugmedicine.medical_specialtyRosiglitazoneSex FactorsInternal medicineDiabetes mellitusmedicineHumansHypoglycemic AgentsAngina UnstableDiabetes Rosiglitazone Cardiovascular RiskHemoglobin A GlycosylatedGlycated HemoglobinHeart FailureIntention-to-treat analysisbusiness.industryBody WeightCholesterol HDLCholesterol LDLtype 2 diabetes; rosiglitazonemedicine.diseaseDrug UtilizationSurgerySulfonylurea CompoundsDiabetes Mellitus Type 2ThiazolidinedionesHydroxymethylglutaryl-CoA Reductase InhibitorsbusinessLancet (London, England)
researchProduct

Local skin necroses after intramuscular injection -Experimental animal studies-.

1977

The pathogenesis of local skin necroses after intramuscular injection of various drugs such as phenylbutazone (Embolia cutis medicamentosa, Nicolau's syndrome) is not clear. In an attempt to simulate this clinical feature experiments were performed on the rabbit ear lobe. A 20% phenylbutazone solution was injected paraarterial, intraarterial and paraarterial after perforation of the vessel. The drug produced a violent inflammation with all kinds of application. The local inflammation induced by paraarterial injection resulted in a fine scarring. Both other kinds of application produced necroses or even perforations. The histological examinations in these cases revealed massive destructions …

MalePathologymedicine.medical_specialtyNecrosisPerforation (oil well)InflammationDermatologyDermatitis ContactInjections IntramuscularSkin DiseasesPathogenesisLesionNecrosismedicinePhenylbutazoneAnimalsSkinbusiness.industryGeneral MedicineSurgerymedicine.anatomical_structurePhenylbutazoneBlood VesselsFemaleRabbitsmedicine.symptombusinessIntramuscular injectionmedicine.drugArteryArchives for dermatological research = Archiv fur dermatologische Forschung
researchProduct